<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01080872</url>
  </required_header>
  <id_info>
    <org_study_id>SA-005</org_study_id>
    <nct_id>NCT01080872</nct_id>
  </id_info>
  <brief_title>Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome</brief_title>
  <acronym>BASE-CFR</acronym>
  <official_title>Coronary Flow Reserve in Patients With Bio-active Stent or Everolimus-eluting Stent Implanted in Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Hospital District of Satakunta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Hospital District of Satakunta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to assess coronary artery reactivity using adenosine-induced coronary
      flow reserve (CFR) by transthoracic echocardiography in patients with Bio-active stent (BAS)
      and Everolimus-eluting stent (EES) distal to the original culprit lesion at 6-8 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The aim of the trial is to assess coronary artery reactivity using
      adenosine-induced coronary flow reserve (CFR) by transthoracic echocardiography in patients
      with Bio-active stent (BAS) and Everolimus-eluting stent (EES) distal to the original culprit
      lesion at 6-8 months.

      Design: BASE-CFR is a substudy of the larger randomized multicenter BASE-ACS trial comparing
      bio-active Titan stent to everolimus-eluting stent in patients with acute coronary syndrome.
      CFR assessment will be performed at 6-8 months after stent implantation at the same time with
      OCT assessment. In-stent restenosis will be ruled out using OCT.

      Primary endpoint: CFR at 6-8 months after stent implantation.

      Secondary endpoint: Coronary flow velocity at baseline and during adenosine-induced hyperemia
      6-8 months after stent implantation..

      Association of CFR to unendotheliazed stent struts and stent malapposition.

      Enrollment: 40 patients (20 receiving BAS and 20 receiving EES).

      Clinical site: Satakunta Central Hospital, Finland Turku University Hospital, Finland
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary flow reserve (CFR)</measure>
    <time_frame>6-8 months after stent implantation</time_frame>
    <description>CFR at 6-8 months after stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coronary flow velocity</measure>
    <time_frame>at baseline and during adenosine-induced hyperemia</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of CFR to unendotheliazed stent struts and stent malapposition</measure>
    <time_frame>6-8 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Titanium-NO coated stent</arm_group_label>
    <description>Patients receiving titanium-nitride-oxide coated stents during the intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus eluting stent</arm_group_label>
    <description>Patients receiving everolimus eluting stents during the intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CFR</intervention_name>
    <description>CFR will be assessed using transthoracic echocardiography with adenosine infusion.</description>
    <arm_group_label>Titanium-NO coated stent</arm_group_label>
    <arm_group_label>Everolimus eluting stent</arm_group_label>
    <other_name>Xience-V stent, Abbott vascular, USA</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with acute coronary syndrome who were treated with BAS or EES during index PCI.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is enrolled to the BASE-ACS trial. Treated culprit lesion is in the
             proximal or middle LAD

          -  Patient or the patient's legal representative has been informed of the nature of the
             study and has provided written informed consent as approved by the Institutional
             Ethics Committee of the respective clinical site

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Treated stent position other than LAD proximal or middle.

          -  EF&lt;30%

          -  Bifurcation lesions

          -  Renal impairment (creatinine &gt;120 mmol/L)

          -  No suitable anatomy for OCT scan or CFR measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuomas O Kiviniemi, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Saraste, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Turku University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pasi P Karjalainen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Ylitalo, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jussi Mikkelsson, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Satakunta Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Satakunta Central Hospital</name>
      <address>
        <city>Pori</city>
        <zip>28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Kiviniemi T. Assessment of coronary blood flow and the reactivity of the microcirculation non-invasively with transthoracic echocardiography. Clin Physiol Funct Imaging. 2008 May;28(3):145-55. doi: 10.1111/j.1475-097X.2008.00794.x. Epub 2008 Feb 26. Review.</citation>
    <PMID>18312446</PMID>
  </reference>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2010</study_first_submitted>
  <study_first_submitted_qc>March 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2010</study_first_posted>
  <last_update_submitted>May 4, 2011</last_update_submitted>
  <last_update_submitted_qc>May 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2011</last_update_posted>
  <responsible_party>
    <name_title>Pasi Karjalainen, MD PhD</name_title>
    <organization>Satakunta Central Hospital</organization>
  </responsible_party>
  <keyword>acute coronary syndrome</keyword>
  <keyword>coronary flow reserve</keyword>
  <keyword>OCT</keyword>
  <keyword>healing</keyword>
  <keyword>drug eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

